The achieved results also have a translational significance considering that we also tested the effect of human recombinant LAV-BPIFB4 on CD14+ PBMCs from ATS patients that confirmed the CXCR4-dependent LAV-BPIFB4 pro-resolving polarizing effects, accompanied by the improvement of the inflammatory balance (e.g., reduced IL-1β and TNF-α levels and increased IL-33 levels) that can contrast the low-grade chronic inflammation affecting the vascular atherosclerotic process (Figure 1) [41]. The gene discussed is BPIFB4; the disease is Andersen-Tawil syndrome.